**Core Concept**
Zileuton is a medication that targets the pathophysiology of asthma by modulating the production of leukotrienes, which are lipid mediators involved in inflammation and bronchoconstriction.

**Why the Correct Answer is Right**
Zileuton specifically inhibits the enzyme 5-lipoxygenase (5-LOX), which is responsible for the conversion of arachidonic acid to leukotriene A4 (LTA4), a key precursor in the synthesis of cysteinyl leukotrienes (CysLTs). By blocking this enzyme, zileuton reduces the levels of CysLTs, leading to decreased inflammation and bronchoconstriction in the airways. This mechanism is particularly beneficial for patients with asthma, as it addresses the underlying pathophysiology of the disease.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because zileuton does not act by inhibiting the enzyme cyclooxygenase (COX), which is involved in the synthesis of prostaglandins and thromboxanes, not leukotrienes.

**Option B:** This option is incorrect because zileuton does not act by blocking the action of histamine receptors, which are involved in the regulation of allergic responses and bronchoconstriction, but are not the primary target of zileuton.

**Option C:** This option is incorrect because zileuton does not act by inhibiting the enzyme phosphodiesterase (PDE), which is involved in the regulation of cyclic nucleotides and smooth muscle relaxation, but is not directly related to the mechanism of action of zileuton.

**Clinical Pearl / High-Yield Fact**
Zileuton is a unique medication that specifically targets the 5-LOX enzyme, making it a valuable option for patients with asthma who require targeted therapy to reduce inflammation and bronchoconstriction.

**Correct Answer:** D. Inhibiting 5-lipoxygenase (5-LOX) enzyme.